Abstract:
A four-period, two-panel, single-rising-dose study (0.1-100 mg) was conducted in healthy males to investigate the pharmacodynamics, tolerability and pharmacokinetics of MK-0434, a steroid 5 alpha-reductase inhibitor. MK-0434 was associated with a significant reduction in dihydrotestosterone, which was maximal at 24 h and maintained through 48 h post treatment. The maximum reduction was approximately 50% and occurred at all doses above 5 mg (10, 25, 50 and 100 mg). MK-0434 appeared to have no effect on serum testosterone at these single doses. Rising single doses of MK-0434 were associated with an increase in Cmax and AUC but the changes were less than proportional to dose, most likely due to nonlinear absorption. MK-0434 given in single doses up to 100 mg was without significant adverse effects in healthy male volunteers. In summary, MK-0434 is a well-tolerated, potent, orally active 5 alpha-reductase inhibitor in man.
Author:
Van Hecken A; Depré M; Schwartz JI; Tjandramaga TB; Winchell GA; De Lepeleire I; Ng J; De Schepper PJ
Address:
Department of Pharmacology, University of Leuven, School of Medicine, Belgium.
Source:
Eur J Clin Pharmacol, 46: 2, 1994, 123-6
Language:
English
Unique Identifier:
94314020
